Oculi Named as a 4th Batch of IC Taiwan Grand Challenge WinnersUnusual Whales·May 12 at 12:21 AMOCS+0.05%OCSAW0.00%
Oculis Advances Targeted Dry Eye Drug Licaminlimab Into Late-Stage TestingTip Ranks·Apr 25 at 04:31 PMOCS+0.05%OCSAW0.00%
Why Oculis Holding (OCS) Is Up 5.5% After Phase 3 DME Trial Milestone – And What's NextSimplywall·Apr 21 at 06:07 AMOCSAW0.00%OCS+0.05%
Oculis Holding (OCS) Is Up 7.9% After EMA PRIME Tag For Optic Neuritis Drug CandidateSimplywall·Apr 4 at 05:48 PMPBE-0.16%OCS+0.05%
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis | OCS Stock NewsStockTitan·Mar 31 at 12:01 AMOCUL+1.33%OCS+0.05%
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting | OCS Stock NewsStockTitan·Mar 16 at 01:01 AMOCSAW0.00%OCS+0.05%
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | OCS Stock NewsStockTitan·Mar 15 at 11:25 PMPBE-0.16%IBB+0.15%
Oculis Posts 2025 Results, Extends Cash Runway and Advances Late-Stage Ophthalmology PipelineTip Ranks·Mar 3 at 10:46 PMBIB+0.16%BBH+0.11%
Oculis Appoints Katie Kazem as Chief Legal Officer | OCS Stock NewsStockTitan·Feb 17 at 01:00 AMARKG+0.02%BBH+0.11%
